Parexel Launches Genomic Medicine Team
The team joined Parexel from GlaxoSmithKline’s Genetics and Computational Biology departments and expands capabilities in genomic-based drug development.
Parexel has expanded services and capabilities in genomic-based drug development with its Genomic Medicine team. The team is comprised of more than 15 scientists with combined expertise in genomics, drug discovery, and drug development, who joined Parexel from GlaxoSmithKline’s Genetics and Computational Biology departments. The team will meet clients’ expected increased needs for the number of personalized medicines that will require genomic information to inform decision-making on the clinical utility and value for the intended patient population.
Read the
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025